**Press Release**
**Media Contacts:**
**IB Communications**
reithera@ibcomms.agency

**ReiThera to Showcase Innovative Viral Vector Platforms at ESGCT 2025**

***Rome, Italy – 09.30.2025*** **– ReiThera Srl**, the Italian leading Contract Development and Manufacturing Organization (CDMO) specialized in the development and GMP manufacturing of viral vectors for gene therapies and vaccines, today announced its participation at the **European Society of Gene & Cell Therapy (ESGCT) Annual Congress 2025**.

ReiThera will welcome attendees at **Booth A25**, where it will highlight its proprietary platforms, advanced technologies, and end-to-end capabilities in scalable process development and manufacturing of viral vectors.

As part of its scientific contribution to the congress, ReiThera will present a series of posters showcasing progress across multiple viral vector platforms:

- **ReiCell-AAV: development and optimization of a scalable high-yield suspension cell line for AAV vector manufacturing**
- **UpGRAde to GRAd32: a clinically ready, thermostable and immunogenic gorilla adenovirus**
- **A novel Gorilla-derived oncolytic Adenovirus with natural selective replication in cancer cells**
- **Integrated platform for recombinant MVA generation, scale-up, and purification using a suspension cell line**

These scientific posters reflect ReiThera's continued commitment to driving innovation in gene and cell therapy manufacturing. With expertise spanning adenoviral, AAV, and MVA platforms, and with facilities equipped for both small- and large-scale GMP production, ReiThera provides flexible, high-quality solutions to accelerate the clinical translation of advanced therapies.

"ESGCT is a pivotal event for the Gene and Cell Therapy community, and we are proud to share our latest advancements with leading researchers, clinicians, and industry partners," said Stefano Colloca, CEO and CTO of ReiThera "Our scientific posters and presence at Booth A25 demonstrate our role as both a technology innovator and a trusted partner for companies worldwide seeking to advance groundbreaking therapies."

ReiThera's participation at ESGCT 2025 underscores its mission to enable the next generation of genetic medicines through scalable, reliable, and regulatory-compliant manufacturing platforms.

**About Reithera**

ReiThera Srl is a CDMO company dedicated to technology and process development and GMP manufacturing, providing support for the clinical translation of genetic vaccines and medicinal products for advanced therapies.

The company has extensive expertise in developing scalable processes for viral-vector manufacturing and a consolidated experience in GMP production of Adeno-Associated Vector (AAV), Lentivirus, Adeno Viral vector (AdV), Modified Vaccinia Ankara and Herpes Simplex Vector.

ReiThera's core manufacturing capacity is based in a state-of-the-art facility, which includes stirred-tank bioreactors at scales of 50L, 200L, 1000L, and 2000L, as well as fixed-bed bioreactors for cell growth in adherence. The GMP facility also comprises a filling suite and quality control laboratories.

ReiThera's headquarters, R&D laboratories, and GMP facilities are located in Rome, Italy. For more information, visit www.reithera.com.